Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
Necitumumab Extends Survival of Patients with Squamous Lung Cancer
By
Wayne Kuznar
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Chicago, IL— Necitumumab, a human immunoglobulin G1 anti-EGFR monoclonal antibody, added to standard chemotherapy significantly improved survival compared with chemotherapy alone as first-line treatment of patients with stage IV non–small-cell lung cancer (NSCLC) of squamous histology.
Read Article
Association Between Indoor Tanning and Melanoma Confirmed in New Meta-Analysis
By
Rosemary Frei, MSc
Melanoma
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Toronto, Ontario—Going to more than 10 indoor tanning sessions over a person’s lifetime is associated with a 34% increased risk of developing melanoma, according to a new meta-analysis presented at the 2014 Canadian Dermatology Association annual meeting.
Read Article
Upfront Docetaxel Markedly Improves Survival
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
August 2014, Vol 5, No 6
Chicago, IL—The upfront addition of docetaxel to androgen deprivation therapy (ADT) adds more than 1 year to overall survival (OS) compared with ADT alone in men with newly diagnosed hormone-sensitive prostate cancer, according to findings from a phase 3 study presented at the 2014 American Society of Clinical Oncology meeting.
Read Article
Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Chicago, IL—Adjuvant exemestane is more effective at preventing breast cancer recurrences than tamoxifen when given with ovarian function suppression (OFS) in young women with hormone receptor–positive early breast cancer, reported Olivia Pagani, MD, Clinical Director, Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, at the 2014 American Society of Clinical Oncology meeting.
Read Article
Guidelines Target Brain Metastases in HER2-Positive Breast Cancer
By
Eileen Koutnik-Fotopoulos
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. Brain metastases are relatively common in patients with HER2-positive metastatic breast cancer, with up to 50% of patients developing metastases over time.
Read Article
ALTTO: Dual Anti-HER2 Adjuvant Therapy No Better than Trastuzumab Alone
By
Phoebe Starr
Breast Cancer
,
Personalized Medicine
,
Value-Based Care
August 2014, Vol 5, No 6
The addition of lapatinib (Tykerb) to trastuzumab (Herceptin) to create dual HER2 blockade was no better than trastuzumab alone in the adjuvant treatment of patients with HER2 breast cancer in the global phase 3 ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trial, reported Martine J. Piccart-Gebhart, MD, PhD, Chair, Breast International Group, Brussels, Belgium, at a plenary session at the 2014 American Society of Clinical Oncology (ASCO) meeting.
Read Article
The Long Road to Rehabilitation: Sandra Wade’s Story on Surviving Breast Cancer
By
Julie K. Silver, MD
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
,
The Patient Perspective
August 2014, Vol 5, No 6
Sandra Wade first e-mailed me on July 15, 2011. As you can see in the excerpts from her correspondence with me below, she asked me to contact her oncologist and let her know that as a breast cancer survivor, Sandra had suffered more than she should have, because she was not referred for rehabilitation services.
Read Article
2014 Oncology Pipeline Looks Impressive
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
August 2014, Vol 5, No 6
The cancer drug pipeline continues to boast many new therapies, reinforcing the recent trends of new and improved monoclonal antibodies and other classes of targeted therapies for different types of tumors.
Read Article
ASCO Guidelines Target Advanced HER2-Positive Breast Cancer
By
Eileen Koutnik-Fotopoulos
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
June 2014, Vol 5, No 5
Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. The American Society of Clinical Oncology (ASCO) released new clinical practice guidelines for the treatment of women with advanced HER2-positive breast cancer, focusing on systemic therapies.
Read Article
PSA Trend Analysis May Help Avoid Unnecessary Biopsies
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2014, Vol 5, No 5
Orlando, FL—Delaying a prostate-specific antigen (PSA)-triggered prostate biopsy to allow for additional PSA assessments might have avoided more than 70% of subsequent biopsies, according to a study of negative biopsies for >28,000 men reported at the 2014 American Urological Association annual meeting.
Read Article
Page 21 of 35
18
19
20
21
22
23
24
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Addressing Cancer Health Disparities: The No One Left Alone Initiative
Rohan Nathwani
,
Arva Patel
,
Warner Kornberg
,
Asutosh Gor, MD
,
Sashi Naidu, MD
,
Viral Rabara, MD
,
Niyati Nathwani, MD
,
Kashyap Patel, MD
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma